Retatrutide 10mg

Name: Retatrutide 10mg
Brand: ProWellness Pharma
Price: 220.0 USD
Availability: InStock

$220.00

$220.00 ~~$250.00~~

Save 12%

Quantity

Size guide

Share

Retatrutide is an experimental medication developed as a potential treatment for obesity and weight-related metabolic disorders. It is a novel, once-weekly injectable peptide that targets multiple pathways in the body related to appetite regulation and energy metabolism. Retatrutide works by acting on specific receptors involved in hunger and satiety, mimicking the effects of hormones such as GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon. This multi-receptor approach aims to enhance weight loss by reducing appetite, increasing energy expenditure, and improving insulin sensitivity, thus promoting more effective and sustainable weight management.

Mechanism of Action: Retatrutide combines the activity of GLP-1, GIP, and glucagon receptors, targeting the central nervous system to help control hunger and regulate fat storage. By working through these three pathways, it can provide a more comprehensive approach to managing obesity and related metabolic conditions such as type 2 diabetes.

Clinical Trial Results:

Phase 2 Trials: In early-phase clinical trials, Retatrutide has shown promising results for weight loss. In a large Phase 2 trial, participants who were administered Retatrutide experienced significant weight reductions, with some individuals losing up to 15-20% of their body weight over a 12-16 week period. This weight loss was achieved with minimal side effects and was sustained in some individuals, demonstrating the potential for long-term management of obesity.

Weight Loss Results:

Participants taking the higher doses of Retatrutide experienced rapid and significant reductions in body weight.
At the highest dose levels, around 60% of participants lost at least 10% of their body weight, with over 30% achieving a loss of 15% or more.
Improvement in Metabolic Health: Clinical trial data also highlighted improvements in various metabolic markers, including insulin sensitivity, blood sugar control, and lipid profiles. Many participants saw reduced fasting glucose levels, improved HbA1c levels, and better cholesterol and triglyceride levels, which suggests that Retatrutide could be an effective treatment for obesity-related metabolic disorders, such as type 2 diabetes.

Safety and Tolerability: The drug was generally well-tolerated in trials, with the most common side effects being gastrointestinal symptoms such as nausea, diarrhea, and reduced appetite. These side effects were typically mild to moderate and tended to improve over time.

Potential for Broader Applications: Beyond weight loss, Retatrutide’s effects on metabolic health also suggest its potential for treating other conditions associated with obesity, such as cardiovascular disease and fatty liver disease. As the drug progresses through further clinical trials, it could potentially be approved for broader use in managing these conditions.

Conclusion: Retatrutide is an exciting new treatment in the field of obesity and metabolic disorders, showing strong promise for significant

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.